Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of THB335 in adults with chronic spontaneous urticaria CSU who continue to experience hives and itching despite treatment with a second-generation H1 antihistamine. This Phase 2, randomized, double-blind, placebo-controlled study aims to compare two doses of THB335 against a placebo. The study is designed for adults aged 18 to 85 who remain symptomatic despite standard care. Participants will be randomly assigned to receive either a higher dose or a lower dose of THB335, or a matching placebo, taken orally once daily for 12 weeks. All participants will continue their stable antihistamine treatment during this period. The study includes a Screening Period of up to 4 weeks before treatment, followed by a 12-week Treatment Period, and then a 4-week Follow-Up Period. During the trial, participants will complete daily electronic diaries to track symptoms such as hives and itching, and attend scheduled study visits for assessments. Researchers will measure changes in weekly Urticaria Activity Score UAS7 and other related scores from baseline to Week 12. Safety will be monitored through the recording of adverse events, vital signs, and laboratory tests up to Week 16. Overall, the total participation time is approximately 20 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.